Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice? 

QoL: Is It a Key Endpoint in the Adjuvant Setting?

Date

19 Sep 2021

Session

Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice? 

Topics

Tumour Site

Urothelial Cancer

Presenters

Matthew Galsky

Authors

M.D. Galsky

Author affiliations

  • Tisch Cancer Institute, The Mount Sinai Hospital - Icahn School of Medicine, 10029 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and Introductions

Presenter: Andrea Necchi

Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice? 

Resources:

Webcast

Live Q&A session

Presenter: James Catto

Session: Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice? 

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.